Bank of America has a strong reputation for keeping the pulse of the financial world, and one of its key tools is the Global Fund Manager Survey, which is conducted monthly and receives views from more than 200 hedge fund, mutual fund and pension fund managers. Those who hold a total of $ 645 billion at AUM. It is the largest regularly conducted survey of its kind. And BofA’s latest findings show that Big Money is confident. More than 90% of investors surveyed have a general belief that 2021 will show a significant recovery from 2020, asset allocations to stocks and commodities are at their highest in 10 years, and global growth is at an all-time high. So, there is a general consensus that now is the time to invest. The only question that remains is what to invest in? Wall Street professionals argue that they are early-stage companies that reflect promising opportunities that mean you’ll get significantly more bang for your buck with low share prices. Moreover, even what appears to be small share price appreciation can result in massive percentage gains. Underline? Not all risks are created equal. To that end, professionals recommend doing some due diligence before making an investment decision. With this in mind, we used the TipRanks database to find attractive penny stocks with bargain price tags. The platform led us to sports stock prices below $ 5 and the analyst community’s “Strong Buy” consensus rating. Not to mention a significant upward potential at the table. ObsEva SA (OBSV) First up is a clinical state biopharmaceutical company with a sharp focus on women’s health. ObsEva is working to develop and commercialize new treatments for women’s reproductive health problems, up to and including pregnancy. The company’s lead drug candidate linzagolix (branded Yselty) is an orally administered GnRH receptor antagonist that has completed two Phase 3 trials, PRIMROSE 1 in the USA and PRIMROSE 2 in both the USA and Europe. Clinical trials enrolled 574 and 535 patients, respectively, and used doses of 100 mg or 200 mg to treat heavy menstrual bleeding associated with uterine fibroids. Results from both studies were positive, supporting the positive safety and efficacy profile of Linzagolix. In an update released last month, ObsEva reported that the European Medicines Agency (EMA) has approved the company to review its Marketing Authorization Application (MAA) for Yselty (100 mg and 200 mg), according to Phase 3 results. Potential MAA approval is expected in Q4: 21. The drug will also be the subject of a New Drug Application (NDA), which will be submitted to the FDA in Q2. With stocks exchanging hands for $ 3.80 each, Wedbush analyst Liana Moussatos sees an attractive entry point for investors. “In our view, Linzagolix has the potential to achieve best-in-class oral GnRH receptor antagonist status based on a flexible dosing regimen with or without reprogramming hormone therapy (ABT), a key differentiator from other GnRH receptor antagonists. Positive PRIMROSE 1 for YSELTY® / UF. and based on PRIMROSE 2 primary endpoint results and additional tracking data, we anticipate annual sales of more than $ 750 million for Linzagolix / UF in 2027, ”Moussatos explained. To this end, Moussatos made a Buy to OBSV with a price target of $ 28. If completed, the potential earnings on cards could be ~ 643%. (Click here to view Moussatos’ past performance.) In general, ObsEva also ranks the unanimous Strong Buy consensus rating on stocks based on the last 3 Buy reviews. As it shows, it impressed its observers. With its 342% return potential, the consensus for the stock price its target is at $ 16.67. (See OBSV stock analysis on TipRanks) BELLUS Health (BLU) The second stock we look at, BELLUS Health is also a clinical-stage biopharmaceutical research company – but the focus here is on a topic few of us think. Hypersensitivity – hypersensitivity or even hypersensitivity to environmental or foreign stimuli – can cause a range of conditions, from chronic cough to serious discomfort. Sometimes less severe chronic symptoms can be the worst. Chronic cough and chronic itching (itchy skin) are mild to moderate symptoms that can be triggered by a number of factors – but when symptoms do not pass, they can have a disproportionately negative impact on quality of life. BLU-5937, the leading drug candidate of BELLUS, continues to work on its effectiveness in the treatment of these symptoms. BLU-5937 is a highly selective PsX3 antagonist that works on the P2X3 receptor in the cough reflex pathway. The current clinical trial is a Phase 2b trial, a follow-up to the Phase 2 RELIEF trial. The RELIEF trial enrolled 68 patients in the US and the UK, 52 of whom completed two test periods. The study showed a statistically significant reduction in cough count in patients with higher baseline numbers. Phase 2b studies are currently enrolling and dosing patients, with intermediate results expected by mid-year, and most important results in the fourth quarter. Speaking of the name of the healthcare industry is RBC Capital analyst Gregory Renza. “We believe that with a proven MOA from clinically successful P2X3 antagonistgefaxipant (MRK), the high selectivity of BLU-5937 can lead to minimal taste effect and provide higher patient compliance and preference than gefapixant, if successful, we anticipate revenues early RCC With peak global sales potential of over $ 900 million in as2024, in addition to indications associated with P2X3 hypersensitivity from the potential label expansion, ”Renza stated.“ Despite the PE missed in the ph.II trial at RCC, the statistics are still in vigilance in patients with high baseline. We believe the decrease in cough frequency indicates the vitality of the POC and asset. “So it shouldn’t be surprising that Renza joins the bulls. The analyst gives the stock a price target of $ 8 with the Outperform rating. This target is the BLU’s ability to increase by ~ 116% over the next twelve months. (Check here to watch Renza’s past performance. If we go back to the rest of the street now, other analysts also liked what they saw. 3 With no Buying and No Hold or No Sale, the word on the street is that BLU is a Strong Buy. At $ 8.67, the average price target indicates ~ 134% upside potential. (See BLU stock analysis on TipRanks) To find good ideas on penny stocks traded with attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that combines all of TipRanks’ stock insights. Disclaimer: The views expressed in this article are those of prominent analysts only. The content is intended for informational use only. It is very important to do your own analysis before making any investment.